AbCellera is a Canadian biotechnology company headquartered in Vancouver, built around a proprietary antibody discovery platform that it licenses to pharmaceutical and biotech partners developing new drug candidates. Listed on Nasdaq under the ticker ABCL.O, the company gained widespread recognition during the COVID-19 pandemic as the discoverer of bamlanivimab, an antibody treatment developed in partnership with Eli Lilly and Company, which brought both revenue and visibility to a business that had previously operated largely below mainstream investor radar.
The underlying business model is distinctive: rather than advancing drugs through the full clinical pipeline itself, AbCellera acts as an upstream discovery partner, taking royalties and milestones as its partners progress candidates towards commercialisation. That royalty-driven structure gives the company long-term revenue potential largely decoupled from the operational complexity of running clinical trials, though near-term income can be lumpy and heavily dependent on partner development timelines.
Please note this is marketing communication, not recommendation or advice.
hesabên mişterî
FxPro ji sala 1999 ve karûbarên bazirganiya serhêl pêşkêşî mişteriyên xwe dike û niha di 173 welatan de xizmet dike.
Xelat
FxPro di pîşesaziyê de her dem nasname wergirtiye û heya niha ji bo kalîteya karûbarên xwe zêdetirî 145 xelata navneteweyî wergirtiye.
xizmeta mişterî
Tîma me ya xizmeta mişterî ya pirzimanî ya fedakar 24/5 dixebite da ku alîkariya we ya bêhempa peyda bike.
rêzikên pîşesaziyê
FxPro di bin çavdêriya rêzikdarî ya hişk a gelek dadweriyê de dixebite, di nav de destûra ji aliyê FCA ve li Keyaniya Yekbûyî — yek ji rêzikdarên darayî yên herî pêbawer ên cîhanî.
